Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
主要な著者: | Xue, L, Hardman, C, Chen, W, Batty, P, Ogg, G, Erpenbeck, V, Sandham, D |
---|---|
フォーマット: | Conference item |
出版事項: |
American Thoracic Society
2018
|
類似資料
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
著者:: Chen, W, 等
出版事項: (2018) -
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
著者:: Sandham, D, 等
出版事項: (2019) -
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
著者:: Hardman, C, 等
出版事項: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
著者:: Xue, L, 等
出版事項: (2019) -
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
著者:: Veit J. Erpenbeck, 等
出版事項: (2016-12-01)